| Bioactivity | LEESGGGLVQPGGSMK acetate, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK acetate can be used for quantitative analysis of Infliximab. Infliximab is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α[1]. | ||||||
| Invitro | The anti-TNF antibodies blocking the action of TNF alpha revolutionized therapy of TNF-related diseases such as Inflammatory Bowel Disease, lupus, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis. By neutralizing TNF activity, anti-TNF antibodies promote mucosal healing and induce long-term remissions in vivo. The main anti-TNF antibodies that are currently authorized encompass Infliximab, Etanercept, Adalimumab, Certolizumab and Golimumab[1]. | ||||||
| Name | LEESGGGLVQPGGSMK acetate | ||||||
| Shortening | LEESGGGLVQPGGSMK | ||||||
| Formula | C66H112N18O26S | ||||||
| Molar Mass | 1605.76 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
LEESGGGLVQPGGSMK acetate
CAS: F: C66H112N18O26S W: 1605.76
LEESGGGLVQPGGSMK acetate, a proteolysis peptide, is a component of Infliximab. LEESGGGLVQPGGSMK acetate can be used for
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.